90
Participants
Start Date
August 27, 2025
Primary Completion Date
February 29, 2028
Study Completion Date
February 29, 2028
SL-APO
"Patients should start with a dose of 10 mg SL-APO. Dose initiation should occur when the patient is having an OFF episode. If the patient tolerates the 10 mg dose, and responds adequately (meaning satisfactory motor response within 30 minutes), the maintenance dose should be 10 mg. If the dose is tolerated but the response is insufficient, continue to titrate in 5 mg increments when the patient is having an OFF episode and assess response until an effective and tolerable dose is achieved, up to a maximum of 30 mg per dose and up to five times a day. If an ON response is achieved and if clinically warranted, consider the need to further up-titrate as tolerated to achieve a better ON response. The minimal interval between doses is 2 hours, with no more than one dose of SL-APO per OFF episode."
NOT_YET_RECRUITING
Charité - Universitätsmedizin Berlin - Sektion für Bewegungsstörungen und Neuromodulation, Berlin
NOT_YET_RECRUITING
Alexianer St. Joseph Berlin-Weißensee GmbH, Berlin
RECRUITING
Praxis für Neurologie, Berlin
RECRUITING
Neurologie am Funkerberg, Wusterhausen
NOT_YET_RECRUITING
Praxis für Neurologie und Psychiatrie, Fulda
NOT_YET_RECRUITING
Katholisches Klinikum Bochum gGmbH, Universitätsklinikum St.Josef-Hospital, Klinik für Neurologie, Bochum
NOT_YET_RECRUITING
Klinik für Neurologie und Neurologische Frührehabilitation, Osnabrück
NOT_YET_RECRUITING
Die Nerven Docs, Siegen
NOT_YET_RECRUITING
Neurologische Klinik Sorpesee, Sundern
NOT_YET_RECRUITING
Praxis für Neurologie und Geriatrie, Ulm
NOT_YET_RECRUITING
UNIVERSITÄTSKLINIKUM FREIBURG - Neurozentrum Klinik für Neurologie und Neurophysiologie im Neurozentrum, Freiburg im Breisgau
NOT_YET_RECRUITING
Klinik am Tharandter Wald, Hetzdorf
Bial - Portela C S.A.
INDUSTRY